Chorus
Please click any link below for our Business-related articles.

"TVM Life Science Ventures VII Announces Investment in GLWL Research Inc."
(TVM|Capital)

"The Arteaus Therapeutics Story: R&D Externalization with Eli Lilly"
(Forbes.com)

"Ixchelsis Gets $14M for Premature Ejaculation Drug"
(BioWorld)

"TVM Life Science Ventures VII announces first investment: Kaneq Bioscience Ltd."
(Yahoo! Finance)

"Teralys Capital and Eli Lilly and Company invest in a new $150 million fund dedicated to the life sciences sector"
(Bloomberg)

"Chorus Celebrates 10th Anniversary with Poster Session"

"Arteaus launches with $18M from Atlas, OrbiMed - licenses a molecule from Eli Lilly for migraine"
(FierceBiotech)

"Arteaus Therapeutics, LLC Raises $18M to Prevent Migraines - Arteaus, using a virtual team and collaborating with Lilly's Chorus unit, will develop an antibody through Phase 2 trials."
(FierceBiotech)

"A More Rational Approach to New-Product Development"
(Harvard Business Review)

"Lilly Sings a New Tune: Chorus Unit Brings High Efficiency Note to Early R&D"
(The Pink Sheet)

"Lilly's Chorus Experiment"
(In Vivo)

"Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept"
(Start-Up)

"Pharma 2020: The vision. Which path will you take?"
(PriceWaterhouseCoopers)

"Transforming Drug Development - A Fully Outsourced Model"
(Pharma Focus Asia - Issue 9)

"An Audience With....Steven Paul"
(Macmillian Pub, January 2009, Volume 8)

"Transforming Drug Development with a Fully Outsourced Model"
(Pharmaceutical Outsourcing May-June 2009)


Please click any link below for our Scientific-related articles.

"Tabalumab in patients with rheumatoid arthritis with an inadequate response to methotrexate and naive to biologic therapy"

"SAFETY, TOLERABILITY AND EVIDENCE OF EFFICACY OF INTRAVENOUS LY2439821 IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BACKGROUND ORAL DMARDs"
(2009)

"Phase 2 Study of Safety and Efficacy of a novel anti-BAFF Monoclonal Antibody, in Patients (Pts) with RA Treated with Methotrexate (MTX)"
(2009)

"LY2439821, a novel anti-IL-17 mAb: Safety,tolerability and efficacy in patients with RA on background DMARDs"
(2009)

If you would like more information about Chorus, please contact us by sending an email to: info@choruspharma.com